Handbook of HER2-Targeted Agents in Breast Cancer (2nd Ed., 2nd ed. 2016)
Langue : Anglais
Auteurs : Alvarez Ricardo H, Cortés Javier, Falzon Mary, Gandy Michael, Gianni Luca, Harbeck Nadia, Piccart Martine
This concise handbook provides oncologists and other healthcare providers with crucial updates in the field, including an updated review of the current understanding of the biology of the HER2 pathway, an overview of HER2-testing, and evidence-based discussions of available and emerging HER2-targeted treatment options. An essential clinical text for physicians that screen and treat patients with breast cancer and require an accessible, up-to-date survey of the dynamic treatment landscape.
Introduction and background biology.- HER2 testing.- HER2-positive breast cancer: neoadjuvant and adjuvant therapy.- HER2-positive metastatic breast cancer: first-line treatment.- HER2-positive metastatic breast cancer: second-line treatment.- Emerging targeted agents for HER2-positive breast cancer.
Ricardo Alvarez is Director of Clinical Research and Breast Cancer Specialist at Cancer Treatment Centers of America in Atlanta, Georgia.
Javier Cortes is Deputy Director of the Breast Cancer Program, Head of the Breast Cancer and Melanoma Group in the Oncology Department of Vall d’Hebron University Hospital in Barcelona, Spain.
Mary Falzon is Consultant histo/cytopathologist and Divisional Clinical Director for University College London Hospitals in London, UK.
Michael Gandy is lead biomedical scientist and clinical services manager at University College London- Advanced Diagnostics in London, UK.
Luca Gianni is the Director of the Department of Medical Oncology at the Hospital San Raffaele in Milan, Italy.
Nadia Harbeck is Head of the Breast Center at the University of Munich and heads the Oncological Therapy and Clinical Trials Unit in Obstetrics and Gynecology in Munich,Germany.
Martine Piccart is Professor of Oncology at the Université Libre de Bruxelles and Director of Medicine at the Jules Bordet Institute, in Brussels, Belgium.
Provides a timely and informative overview of the role of HER2 in breast cancer and the implications for treatment Includes evidence-based discussion of major clinical trials and the most recent guidelines for diagnosis and treatment of HER2-positive breast cancer Written by leading experts in the field of breast oncology and histopathology Includes supplementary material: sn.pub/extras
Date de parution : 05-2016
Ouvrage de 110 p.
12.7x20.3 cm
Thèmes de Handbook of HER2-Targeted Agents in Breast Cancer :
Mots-clés :
Breast cancer; Cancer; HER2; HER2-positive; Oncology; Pertuzumab; Trastuzumab; Diagnostic Radiology
© 2024 LAVOISIER S.A.S.
